Biosceptre is developing a multi-targeted universal CAR-T system, designed to incorporate our nfP2X7 technology, to be capable of treating a range of cancers.
Headquarters:
United Kingdom of Great Britain and Northern Ireland
Company Type:
SME
Company size:
11-50 Employees
Address:
BABRAHAM HALL; BABRAHAM RESEARCH CAMPUS; CAMBRIDGE, CB22 3AT, GB
LOW
spending power